Mankind Pharma to take over Panacea Biotec Pharma

Mankind Pharma buys Panacea unit

by 5paisa Research Team Last Updated: Dec 10, 2022 - 02:58 pm 37.2k Views
Listen icon

Mankind Pharma will buy the domestic formulations business of Panacea Biotec Pharma, a subsidiary of Panacea Biotec. The total consideration for the purchase will be around Rs.1,872 crore. Panacea Biotech is best known as the manufacturer of Sputnik-V, the Russian vaccine to tackle COVID pandemic. Panacea Biotec board approved the decision to sell the formulations business as per a filing with the stock exchanges.

While Panacea Biotec sells the domestic formulations business it will also include the formulations brands in India and Nepal, all the related trademarks, copyrights etc belonging to its subsidiary Panacea Biotec Pharma. Panacea Biotec Pharma and Mankind Pharma have already entered into a binding term sheet on January 31. In response, the stock of Panacea Biotec was already up by 5% on the BSE.

Panacea Biotec Pharma was struggling to repay debt and was badly in need of funds. Piramal Enterprises and India Resurgence Fund had extended the repayment date last year after the company said that it did not have the cash. This deal will infuse the necessary cash and will also allow Panacea to service the debt. The company has a pay-out of nearly Rs.750 crore to be done in the current year and now that should be a smooth affair.

The parent, Panacea Biotec, had transferred its pharma formulations business and its formulations facility at Baddi, apart from the related R&D and natural products extraction activities at Lalru to Panacea Biotec Pharma, its wholly owned subsidiary, in the year 2020. Incidentally, Serum Institute of India CEO Adar Poonawalla holds 8.59% stake in Panacea Biotec in his personal capacity. The parent is into vaccines and pharmaceutical products.

Under the terms of the deal, Mankind Pharma will retain Panacea's sales and marketing team fully and integrate them into the parent. The acquisition will be value accretive for Mankind Pharma as it will allow them to explore new therapeutic areas and also to create visibility in lifestyle, oncology and transplant business.

How do you rate this blog?

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage


About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.

Enjoy 0%* Brokerage with 5paisa
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest Blogs
Market Outlook for 23 April 2024

Nifty started the week on a positive note above 22300 mark. The index consolidated within a range throughout the day and ended around its day’s high above 22350 with gains of a percent. Nifty Today:

Market Outlook for 22 April 2024

Our markets corrected sharply in the week gone by mainly due to uncertainty over global geopolitical tensions and selling by the FIIs which resulted in the index breaking the 22000 mark. However, we witnessed recovery from the low of 21780 in the last trading session and Nifty ended around 22150 with a weekly loss of over one and a half percent.

Stock in Action - Escorts Kubota Ltd

Escorts Kubota Stock Movement of Day